Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1034 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

CASE REPORT Table of Contents   
Year : 2020  |  Volume : 31  |  Issue : 2  |  Page : 521-523
Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide

1 Department of Nephrology, Institute of Nephro-urology, Bengaluru, Karnataka, India
2 Department of Nephropathology, Manipal Hospitals, Bengaluru, Karnataka, India

Correspondence Address:
Umesh Lingaraj
Department of Nephrology, Institute of Nephro-urology, Victoria Hospital Campus, Bengaluru - 560 002, Karnataka
Login to access the Email id

DOI: 10.4103/1319-2442.284029

PMID: 32394927

Rights and Permissions

Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded166    
    Comments [Add]    

Recommend this journal